Drug intelligence / Profile preview

miR-520b

Development stage: Preclinical
Lead developer: Chang Gung University
Modality: RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Parenteral

Overview

miR-520b is a microRNA that acts as a tumor suppressor by targeting the CD44 molecule. In head and neck cancer (HNC), miR-520b has been shown to inhibit the cancer stem cell phenotype, reducing cellular migration, invasion, and epithelial-mesenchymal transition (EMT). It also sensitizes cancer cells to chemotherapy and radiotherapy. Preclinical studies in xenograft models demonstrate that administration of miR-520b mimics can restrain tumorigenesis and liver colonization, while its silencing accelerates tumor growth.

Other names: hsa-miR-520bhsa-miR520bhsa-miR 520bmicroRNA-520bmicroRNA520bmicroRNA 520b

Targets

PTEN (Phosphatase and tensin homolog deleted on chromosome ten)CD44 (CD44 antigen)

Beyond the preview

Go deeper on miR-520b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-520b.

Explore the full profile